The HRT black box warning is gone. Here's what actually changed.
The FDA has removed the boxed "black box" warning from systemic menopausal hormone therapy. The labeling changes were approved in February 2026. What came off the label was the single most-severe warning that lumped every menopausal estrogen and estrogen-plus-progestin product together under risks (stroke, blood clots, breast cancer, dementia) drawn largely from a 2002 trial of much older women. It was not a finding that HRT is now risk-free.
What remains matters just as much: a woman with a uterus who takes systemic estrogen still needs a progestogen to avoid endometrial (uterine) cancer from unopposed estrogen, clot and stroke risks are still noted, and HRT is still not approved to prevent heart disease or dementia. The evidence favors starting before age 60 or within 10 years of menopause. Below is what was removed, what stayed, and what it changes for a real prescription.
General information, not medical advice. See the full disclaimer at the end.
What did the FDA actually remove from the HRT label?
One thing: the boxed warning(the black-bordered box at the top of a drug label, the agency's strongest safety alert) that appeared on systemic menopausal hormone therapy: oral, transdermal, and injectable estrogen and estrogen-plus-progestin products used to treat menopause symptoms. The FDA announced the initiative on November 10, 2025, and approved the labeling changes in February 2026. The boxed warning had presented a class-wide list of the most serious risks (cardiovascular events, stroke, venous clots, breast cancer, and probable dementia) at the top of essentially every menopausal HT label, regardless of the woman's age, the dose, or the delivery route. Removing the box does not delete those risks from the label; it moves the discussion out of a one-size-fits-all alarm and into the sections where risk can be described by context.
Why was the black box warning there in the first place?
The boxed warning traces to the Women's Health Initiative (WHI), whose hormone trials were halted in 2002 after early signals of increased breast cancer, stroke, and clot risk. Two facts about that trial explain the mismatch that followed: the average participant was in her early-to-mid 60s, well past the typical menopause transition, and the regimen studied was a specific one, oral conjugated equine estrogen with a synthetic progestin (medroxyprogesterone). Regulators applied a boxed warning across the whole menopausal-HT class, and prescribing fell sharply for two decades. Later reanalyses found the risk-benefit balance looks very different for younger women starting closer to menopause and for transdermal routes, the evidence base the 2026 label change is built on.
Did the FDA hold an advisory panel before removing the warning?
Yes, and it is routinely misdated. The review that led to this label change was the FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women, held on July 17, 2025 from 1:00 to 3:00 p.m. ET. Not June 2026, which is a date that circulates in coverage of the label change and does not match any FDA panel record. The 12 panelists were named publicly and included JoAnn E. Manson, MD, DrPH (chief of preventive medicine at Brigham and Women's Hospital and a WHI investigator), JoAnn V. Pinkerton, MD (past president of The Menopause Society), and Howard N. Hodis, MD (director of the Atherosclerosis Research Unit at USC). The panel weighed breast cancer, uterine cancer, and cardiovascular risk against benefits to bone, genitourinary, cardiovascular, and cognitive health, and specifically examined how that balance shifts with age at initiation, formulation, and dose. The FDA then opened a public docket for comment, which closed at 11:59 p.m. ET on September 24, 2025.
The chronology matters if you are trying to work out how settled this is, so here it is with real dates: panel July 17, 2025, FDA initiates removal November 2025 after what it called a comprehensive review of the scientific literature, labeling changes approved for the first six products February 12, 2026. Twenty-nine drug companies submitted proposed labeling changes at the FDA's request, so more products follow those six. The agency's own stated basis for the timing rule is that randomized studies show women who start HRT within 10 years of the onset of menopause, generally before age 60, have a reduction in all-cause mortality and fractures.
The FDA also put a number on how few women use these drugs: in 2020 about 41 million U.S. women were aged 45 to 64, and about 2 million women aged 46 to 65 received a hormone therapy prescription. That gap is the reason the agency gave for acting on the label at all.
Removing the box is not the same as removing the risks. The following still appear in the labeling and in clinical guidance, and are the things to actually discuss with a prescriber:
Endometrial (uterine) cancer from unopposed estrogen. This is the single most important remaining warning. If you have a uterus and take systemic estrogen, you also need a progestogen to protect the uterine lining. Estrogen alone is appropriate only after hysterectomy. For the most commonly prescribed one, we have pulled every micronized progesterone side effect from the label with the placebo rate beside it.
Venous blood clots and stroke. Still noted, and route matters: oral estrogen carries a higher clot risk than transdermal (patch, gel, spray), which is why clinicians often prefer transdermal for women with clot risk factors.
Not for prevention of heart disease or dementia. Menopausal HT is approved to treat symptoms (and to prevent osteoporosis in appropriate patients), not as a cardiovascular or cognitive prophylactic. An August 2026 cohort in Neurology reported lower odds of Alzheimer pathology at autopsy among estrogen-only HRT users, and its authors state the result does not address causality: what that study found, and what it did not.
Breast-cancer nuance. The signal is tied mainly to longer-duration estrogen-plus-progestin therapy; estrogen-alone data differ. It is a conversation about duration and personal history, not a blanket contraindication.
The timing rule: who benefits, and who should be cautious
The clearest practical takeaway from the modern evidence is timing. For women who begin hormone therapy before age 60 or within 10 years of their last menstrual period, benefits (symptom relief, bone protection) generally outweigh risks. Begin much later (more than a decade past menopause or after 60) and the balance shifts, with cardiovascular and stroke risk weighing more heavily. Timing is also why a boxed warning built on a trial of women in their 60s never described the risk faced by a 52-year-old starting HRT for hot flashes. Some women should still avoid systemic HRT regardless of timing, including those with a history of hormone-sensitive cancer, active or prior blood clots, active liver disease, or unexplained vaginal bleeding, which is exactly why the decision belongs to you and a clinician.
What does the change mean for my prescription in practice?
Less than the headlines suggest, and more than nothing. The medicine is unchanged: same molecules, same routes, same need for a progestogen if you have a uterus. What changes is the surrounding fear: a generation of clinicians trained to see a black box at the top of every HRT label now has a label that reflects age, dose, and route. Expect easier conversations, not automatic prescriptions. Practically, three things still hold: transdermal estrogen is often the starting preference for clot safety; progestogen coverage is non-negotiable with an intact uterus; and dose and duration are individual. The change also arrives alongside a surge in demand that has strained estradiol patch supply, so the route you and your clinician choose may partly depend on what a pharmacy can actually fill.
Frequently asked questions
Is HRT safe now that the black box warning is gone in 2026?+
The label change reflects a more accurate reading of the evidence, not a declaration that HRT is risk-free. For most healthy women who start within 10 years of menopause or before age 60, menopausal hormone therapy's benefits generally outweigh its risks. Real risks remain: endometrial cancer from unopposed estrogen, blood clots (higher with oral than transdermal estrogen), and individual contraindications. So the decision is still made with a clinician, not by the label alone.
What warning still remains on HRT after the black box removal?+
The most important remaining warning is endometrial (uterine) cancer risk from unopposed estrogen: a woman with a uterus who takes systemic estrogen must also take a progestogen to protect the uterine lining. Labels also continue to note risks such as venous blood clots and stroke, and state that these products are not approved to prevent heart disease or dementia. What the FDA removed was the single boxed warning that applied the most severe risks to the whole class regardless of age, dose, or route.
What is the under-60 / within-10-years HRT rule?+
It is the timing hypothesis, sometimes called the 'window of opportunity.' For women who begin hormone therapy before age 60 or within 10 years of their last period, the balance of benefits and risks is generally favorable. Starting more than 10 years after menopause, or after age 60, shifts that balance: cardiovascular and stroke risk weigh more heavily. The timing rule is why a class-wide boxed warning derived from a trial of older women was a poor fit for the women most likely to be prescribed HRT today.
Did the FDA hold an advisory panel before removing the HRT black box warning?+
Yes. The FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women met on July 17, 2025, not in June 2026 as some coverage states. Twelve named panelists, including WHI investigator JoAnn E. Manson and past Menopause Society president JoAnn V. Pinkerton, reviewed breast cancer, uterine cancer, and cardiovascular risk against benefits to bone, genitourinary, cardiovascular, and cognitive health, with attention to how the balance changes by age at initiation, formulation, and dose. The FDA opened a public comment docket that closed September 24, 2025, initiated removal of the boxed warnings in November 2025, and approved the first six revised labels on February 12, 2026.
Does removing the black box warning change my prescription?+
In practice it lowers the fear that kept many women and clinicians away from HRT, but the medicine itself is unchanged. You still need a prescriber, you still need a progestogen alongside systemic estrogen if you have a uterus, and transdermal routes (patch, gel, spray) are still often preferred over oral for clot risk. The change makes the conversation easier and the label more honest; it does not make HRT a self-serve or one-size-fits-all treatment.
This is general information, not medical advice. HRT is a prescription medical treatment; whether it is right for you, at what dose, and by which route depends on your health history and must be decided with a licensed clinician. HRT Picks is not a medical provider and has no role in your care. This guide was reviewed against the primary sources cited above on July 30, 2026.
Some links above are affiliate links. We may earn a commission at no extra cost to you. Scores are methodology-only and never move for affiliate status. How we score.
Midi Health
Sesame Care